about
Neural KCNQ (Kv7) channelsInactivation as a new regulatory mechanism for neuronal Kv7 channelsThe acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytesDominant-negative inhibition of M-like potassium conductances in hair cells of the mouse inner earNeuronal Ca2+-activated K+ channels limit brain infarction and promote survivalCritical role of large-conductance calcium- and voltage-activated potassium channels in leptin-induced neuroprotection of N-methyl-d-aspartate-exposed cortical neurons.Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673.Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370Novel anticonvulsant medications in development.KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.The therapeutic potential of neuronal KCNQ channel modulators.Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders.Reconstruction of Cell Surface Densities of Ion Pumps, Exchangers, and Channels from mRNA Expression, Conductance Kinetics, Whole-Cell Calcium, and Current-Clamp Voltage Recordings, with an Application to Human Uterine Smooth Muscle Cells.Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.Dynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channels.K+ channel modulators for the treatment of neurological disorders and autoimmune diseasesPharmacological modulation of voltage-gated potassium channels as a therapeutic strategy.Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells.Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels.A-272651, a nonpeptidic blocker of large-conductance Ca2+-activated K+ channels, modulates bladder smooth muscle contractility and neuronal action potentials.The Voltage-Sensing Domain of K(v)7.2 Channels as a Molecular Target for Epilepsy-Causing Mutations and Anticonvulsants.Restoration of ion channel function in deafness-causing KCNQ4 mutants by synthetic channel openers.Enhancing m currents: a way out for neuropathic pain?Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.Voltage-independent KCNQ4 currents induced by (+/-)BMS-204352.The KCNQ/M-current modulates arterial baroreceptor function at the sensory terminal in rats.Perivascular adipose tissue and the dynamic regulation of Kv 7 and Kir channels: Implications for resistant hypertension.Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket
P2860
Q24644947-6687219C-0FE1-4247-841F-322B35AB1DA8Q24676507-5FA57A7A-B446-4BAC-B764-96E284C7D416Q28472214-62CF0390-E824-4214-B7BF-AF4945626DD0Q30440196-E48D81A5-2F44-489C-A435-BAB75C2B3DC6Q33786915-8D2F8890-3E02-43AC-BA96-32C9B8F69010Q34053697-CBBB641F-F0CC-42E1-A89E-EE12E2088ADBQ34114419-DFE4BD1E-26D1-4A63-BF6D-7703D383560EQ34125218-0ABF4A56-F112-4E5E-9F58-3082857CFCDAQ34402797-F09478B3-7A88-469A-8A9D-2A1B10AB4AE7Q34974862-DFF66D8A-DAA2-41CC-884C-4D7E92F0A72FQ35228397-8E2E706A-764F-42E3-8AE8-2409F09CE15DQ35593939-E96DF0F7-5B3B-46E7-9A5C-4C19C2B1F176Q35683922-8002BE1C-89E0-4647-A243-4D68584B2149Q35911129-4E141699-146E-4A1D-9510-D489306599B0Q35997094-0F308BA0-A4EF-4886-87C7-34DA8F034A8AQ36498532-E23ABAF1-FB64-4DA6-9402-553800FA6FD6Q36576250-8659613C-58AE-4E17-89E1-FF3BF264C445Q36884182-5F0CCC06-88C9-4F2F-B1E6-04508AA70BB2Q37162392-A2B01C8E-F037-4C04-89B5-634869A934E9Q37781356-28FDEEE2-A8B3-4B95-AB69-25F4CC26E6CCQ39676867-A9F1A2C9-BE3C-48F6-81A5-CF740DF0FE65Q40464186-C92CCBFB-64F9-474B-8239-9A05CEEEEA50Q41590912-7A9DF1A4-83BA-4AD9-B56A-86490685F1F3Q41879401-620C700A-3DCD-4B7E-AF37-25C7F5DC3C23Q42265492-3AE82C30-0B29-4593-BA9B-C1AD56377426Q43071251-7CFFAEE5-03EB-42C2-B0A5-A2EC4A49EE45Q44408542-D2F258E5-B3C9-4C35-9D87-63282A180394Q44507292-4B3966D4-674B-4E02-BD61-7E0B35F50A21Q46874608-C9C4E878-4BA2-4420-8765-93245D00E566Q47656632-DE893B4E-F7C4-4B4D-A6D1-DAF70642F486Q57921983-78D18563-F440-4591-96DA-AA3C06C92E20
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
KCNQ4 channel activation by BMS-204352 and retigabine.
@en
type
label
KCNQ4 channel activation by BMS-204352 and retigabine.
@en
prefLabel
KCNQ4 channel activation by BMS-204352 and retigabine.
@en
P2093
P1433
P1476
KCNQ4 channel activation by BMS-204352 and retigabine.
@en
P2093
B S Jensen
D Strøbaek
P Christophersen
R L Schrøder
S P Olesen
P304
P356
10.1016/S0028-3908(01)00029-6
P577
2001-06-01T00:00:00Z